Lantheus names new CEO, board chair

| | Health Imaging | Molecular Imaging

Lantheus Medical Imaging has appointed Jeffrey A. Bailey as its president, CEO and a member of the board of directors, and Brian A. Markison as chairman of the board.

Bailey replaces Donald Kiepert, who resigned from Lantheus to pursue other opportunities. Bailey brings more than 26 years of diverse pharmaceutical leadership experience across multiple functions, including sales, marketing, manufacturing, supply chain and operations. Additionally, Brian A. Markison, who joined Lantheus’ board of directors in September 2012, has been appointed as chairman of the board.

Bailey most recently served as CEO and a member of the executive committee of Fougera Pharmaceuticals, where he led the company’s generic and branded pharmaceuticals products. Prior to joining Fougera in August 2011, Bailey served as the chief commercial officer of King-Pfizer Pharmaceuticals, leading a team of 750 members. Earlier, he worked with Novartis Pharmaceuticals as president and general manager, as well as Janssen Pharmaceutica. 

 

 

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.